

Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A propensity score matching analysis

Takashi Niizeki¹, Takayuki Tokunaga², Yuko Takami³, Yoshiyuki Wada³, Masaru Harada⁴, Michihiko Shibata⁴, Kazuhiko Nakao⁵, Ryu Sasaki⁵, Fumihito Hirai⁶, Satoshi Shakado⁶, Tomoharu Yoshizumi⁷, Shinji Itoh⁷, Hiroshi Yatsushashi⁸, Shigemune Bekki⁸, Akio Ido⁹, Seiichi Mawatari⁹, Koichi Honda¹⁰, Rie Sugimoto¹¹, Takeshi Senju¹¹, Hirokazu Takahashi¹², Takuya Kuwashiro¹³, Tatsuji Maeshiro¹⁴, Makoto Nakamuta¹⁵, Yoshifusa Aratake¹⁵, Tsutomu Yamashita¹⁶, Yuichiro Otsuka¹⁶, Shuichi Matsumoto¹⁷, Tetsuro Sohda¹⁸, Shigeo Shimose^{1*}, Kenta Murotani¹⁹, Yasuhito Tanaka²: Kyushu Liver Cancer Study Group of Japan

1. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan

2. Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

3. Department of Hepato-Biliary-Pancreatic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

4. Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

5. Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.

6. Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
7. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
8. Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 2-1001-1 Kubara, Omura, Nagasaki, 856-8562, Japan.
9. Department of Human and Environmental Sciences, Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
10. Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan
11. Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
12. Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University
13. Liver Center, Saga University Hospital, Faculty of Medicine, Saga University
14. First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan
15. Department of Gastroenterology and Hepatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
16. Department of Gastroenterology, National Hospital Organization Oita Medical Center
17. Department of Gastroenterology, Fukuoka Tokushukai Hospital, Kasuga,

Japan.

18. Department of Hepatology, Japanese Red Cross Fukuoka Hospital,
Fukuoka, Japan.

19. Biostatistics Center, Graduate School of Medicine, Kurume University

Supplementary Table 1. Response rate according to modified-RECIST before PSM

Response category	Atezo/Beva (n=161)	LEN (n=568)	p
CR	17 (10.6%)	40 (7.0%)	
PR	54 (33.6%)	230 (40.5%)	
SD	72 (44.7%)	189 (33.2%)	
PD	18 (11.1%)	109 (19.3%)	
ORR	67 (44.2%)	270 (47.5%)	0.440
DCR	143 (88.9%)	459 (80.7%)	0.013

Abbreviations: Atezo/beva; atezolizumab plus Bevacizumab, LEN; Lenvatinib, CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate

Supplementary Table 2. Response rate according to modified-RECIST after PSM

Response category	Atezo/Beva (n=152)	LEN (n=152)	p
CR	17 (11.2%)	13 (8.5%)	
PR	50 (32.9%)	58 (38.2%)	
SD	70 (46.1%)	49 (32.2%)	
PD	15 (9.8%)	32 (21.1%)	
ORR	67 (44.8%)	71 (46.7%)	0.644
DCR	137 (90.2%)	120 (78.9%)	0.006

Abbreviations: Atezo/beva; atezolizumab plus Bevacizumab, LEN; Lenvatinib, CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate

Supplementary Figure 1.




Figure legends

Supplementary Figure 1. C-statics by using ROC analysis.